Also trades as: AUP.TO (TSX) · $vol 4M
AUPH NASDAQ
Aurinia Pharmaceuticals Inc.
1W: +3.3%
1M: +3.6%
3M: +13.9%
YTD: +11.0%
1Y: +47.1%
3Y: +128.1%
5Y: -13.5%
$17.25
+0.21 (+1.23%)
Weekly Expected Move ±3.3%
$16
$16
$17
$17
$18
Credit Risk of going bust: lower than 86% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.04 (down 99.8%), Aurinia Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $60.4M against a stock market value of $2.27B.
Distance to default 11.63 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.2M (short-term plus half of long-term), stock volatility 37.5%; Altman Z'' 6.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $60.4M against a stock market value of $2.27B.
Distance to default 11.63 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.2M (short-term plus half of long-term), stock volatility 37.5%; Altman Z'' 6.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$12.5M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.3B
52W Range11.885-19.25
Volume794,700
Avg Volume1,215,537
Beta1.41
Dividend—
Analyst Ratings
Company Info
CEOKevin C. Tang
Employees128
SectorHealthcare
IndustryBiotechnology
IPO Date2014-09-03
Websiteauriniapharma.com
#140, 14315 â 118 Avenue
Edmonton, AB T5L 4S6
CA
Edmonton, AB T5L 4S6
CA
12507084272
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Latest News
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
Aurinia Pharmaceuticals Inc $AUPH Shares Sold by Engineers Gate Manager LP
Bank of New York Mellon Corp Invests $5.95 Million in Aurinia Pharmaceuticals Inc $AUPH
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Robertson Stephen P. | S-Sale | 11,939 | $15.95 | 2026-09-10 |
| Robertson Stephen P. | S-Sale | 20,975 | $16.97 | 2026-08-21 |
| Johnson Craig A | A-Award | 23,931 | $15.67 | 2026-06-04 |
| Goetz Kathleen | A-Award | 23,931 | $15.67 | 2026-06-04 |
| Nova Tina Susan | A-Award | 23,931 | $15.67 | 2026-06-04 |